Cibenzoline is an antiarrhythmic agent that inhibits the KATP channel by directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline shows little anticholinergic activity. Cibenzoline markedly reduces LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for hypertrophic obstructive cardiomyopathy research[1][2].
Molecular Weight:
262.35
CAS Number:
[53267-01-9]
Formula:
C18H18N2
Target:
Potassium Channel|||Others
T60428
* VAT and and shipping costs not included. Errors and price changes excepted
